Published in Future Med Chem on September 01, 2011
Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar Drugs (2014) 1.26
Baulamycins A and B, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in Staphylococcus aureus and Bacillus anthracis. J Am Chem Soc (2014) 1.04
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012. Mar Drugs (2015) 1.00
Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2-ARE pathway. Free Radic Biol Med (2013) 0.91
Marine Peptides: Bioactivities and Applications. Mar Drugs (2015) 0.90
Major bioactive metabolites from marine fungi: A Review. Bioinformation (2015) 0.85
Spongosine production by a Vibrio harveyi strain associated with the sponge Tectitethya crypta. J Nat Prod (2015) 0.84
Brominated skeletal components of the marine demosponges, Aplysina cavernicola and Ianthella basta: analytical and biochemical investigations. Mar Drugs (2013) 0.83
Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glacialis L. in neuroblastoma cells. Mar Drugs (2013) 0.83
Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci (2014) 0.83
Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition. Mar Drugs (2013) 0.82
Bioactive marine drugs and marine biomaterials for brain diseases. Mar Drugs (2014) 0.81
Antibacterial Derivatives of Marine Algae: An Overview of Pharmacological Mechanisms and Applications. Mar Drugs (2016) 0.81
The marine metabolite SZ-685C induces apoptosis in primary human nonfunctioning pituitary adenoma cells by inhibition of the Akt pathway in vitro. Mar Drugs (2015) 0.81
Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway. Nat Commun (2016) 0.81
Anti-Inflammatory and Analgesic Effects of the Marine-Derived Compound Excavatolide B Isolated from the Culture-Type Formosan Gorgonian Briareum excavatum. Mar Drugs (2015) 0.80
Total synthesis of 7'-desmethylkealiiquinone, 4'-desmethoxykealiiquinone, and 2-deoxykealiiquinone. J Org Chem (2014) 0.79
Advances in the study of the structures and bioactivities of metabolites isolated from mangrove-derived fungi in the South China Sea. Mar Drugs (2013) 0.79
Identification of eusynstyelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell analyzer. Mar Drugs (2014) 0.78
Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds. Mar Drugs (2016) 0.78
Recent advances and applications of experimental technologies in marine natural product research. Mar Drugs (2015) 0.77
Synthetic strategies to terpene quinones/hydroquinones. Mar Drugs (2012) 0.77
A new benzofuran glycoside and indole alkaloids from a sponge-associated rare actinomycete, Amycolatopsis sp. Mar Drugs (2014) 0.77
Targeted metagenomics as a tool to tap into marine natural product diversity for the discovery and production of drug candidates. Front Microbiol (2015) 0.76
Antimicrobial rubrolides from a South African species of Synoicum tunicate. J Nat Prod (2012) 0.76
Preparative separation of sulfur-containing diketopiperazines from marine fungus Cladosporium sp. using high-speed counter-current chromatography in stepwise elution mode. Mar Drugs (2015) 0.76
In Vitro Anti-Inflammatory and Cytotoxic Effects of Aqueous Extracts from the Edible Sea Anemones Anemonia sulcata and Actinia equina. Int J Mol Sci (2017) 0.75
Molecular targets of luteolin in cancer. Eur J Cancer Prev (2016) 0.75
A Coral-Derived Compound Improves Functional Recovery after Spinal Cord Injury through Its Antiapoptotic and Anti-Inflammatory Effects. Mar Drugs (2016) 0.75
Four Aromatic Sulfates with an Inhibitory Effect against HCV NS3 Helicase from the Crinoid Alloeocomatella polycladia. Mar Drugs (2017) 0.75
Integrated (Meta) Genomic and Synthetic Biology Approaches to Develop New Biocatalysts. Mar Drugs (2016) 0.75
Insights into the structure-activity relationship of the anticancer compound ZJ-101, a derivative of marine natural product superstolide A: A critical role played by the conjugated trienyl lactone moiety. Bioorg Med Chem Lett (2016) 0.75
PROSPECTIVE EFFECT OF RED ALGAE, ACTINOTRICHIA FRAGILIS, AGAINST SOME OSTEOARTHRITIS AETIOLOGY. Afr J Tradit Complement Altern Med (2016) 0.75
Anthraquinones and Derivatives from Marine-Derived Fungi: Structural Diversity and Selected Biological Activities. Mar Drugs (2016) 0.75
Contemporary Strategies for the Synthesis of Tetrahydropyran Derivatives: Application to Total Synthesis of Neopeltolide, a Marine Macrolide Natural Product. Mar Drugs (2016) 0.75
A metabolomics guided exploration of marine natural product chemical space. Metabolomics (2016) 0.75
Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. Med Res Rev (2016) 0.75
Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials. Mar Drugs (2017) 0.75
Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products. Antimicrob Agents Chemother (2017) 0.75
Polycyclic Furanobutenolide-Derived Cembranoid and Norcembranoid Natural Products: Biosynthetic Connections and Synthetic Efforts. Chem Rev (2017) 0.75
A bacterium that can grow by using arsenic instead of phosphorus. Science (2010) 14.35
The Sorcerer II Global Ocean Sampling expedition: expanding the universe of protein families. PLoS Biol (2007) 13.99
Natural products as sources of new drugs over the last 25 years. J Nat Prod (2007) 13.98
Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol (2006) 5.78
Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proc Natl Acad Sci U S A (2005) 5.02
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl (2003) 4.50
Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci U S A (2007) 4.04
Marine natural products. Nat Prod Rep (2010) 3.68
Marine natural products. Nat Prod Rep (2010) 3.22
Marine natural products as anticancer drugs. Mol Cancer Ther (2005) 2.93
The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci (2010) 2.47
Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A (2009) 2.40
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc (2008) 2.34
Antagonistic interactions among marine pelagic bacteria. Appl Environ Microbiol (2001) 2.29
Automated genome mining for natural products. BMC Bioinformatics (2009) 2.29
Genome mining for novel natural product discovery. J Med Chem (2008) 2.22
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem (2004) 2.11
A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther (2010) 2.10
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry (2010) 2.07
Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc (2001) 2.06
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina. Appl Environ Microbiol (2001) 1.94
Biosynthetic characterization and chemoenzymatic assembly of the cryptophycins. Potent anticancer agents from cyanobionts. ACS Chem Biol (2006) 1.94
Enzymatic total synthesis of enterocin polyketides. Nat Chem Biol (2007) 1.78
Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem (2008) 1.77
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc (2008) 1.76
Ammosamides A and B target myosin. Angew Chem Int Ed Engl (2009) 1.74
Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today (2000) 1.74
Sporolides A and B: structurally unprecedented halogenated macrolides from the marine actinomycete Salinispora tropica. Org Lett (2005) 1.72
Pyocyanin isolated from a marine microbial population: synergistic production between two distinct bacterial species and mode of action. Chem Biol (2006) 1.70
Organic structure determination using atomic-resolution scanning probe microscopy. Nat Chem (2010) 1.68
Induced production of emericellamides A and B from the marine-derived fungus Emericella sp. in competing co-culture. J Nat Prod (2007) 1.56
Towards prediction of metabolic products of polyketide synthases: an in silico analysis. PLoS Comput Biol (2009) 1.53
Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol (2010) 1.47
The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol (1999) 1.47
Pharmaceutically active natural product synthesis and supply via plant cell culture technology. Mol Pharm (2008) 1.45
GenBank and PubMed: How connected are they? BMC Res Notes (2009) 1.44
Identification of direct protein targets of small molecules. ACS Chem Biol (2010) 1.44
Trading molecules and tracking targets in symbiotic interactions. Nat Chem Biol (2008) 1.42
Antiviral lead compounds from marine sponges. Mar Drugs (2010) 1.40
Engineering fluorometabolite production: fluorinase expression in Salinispora tropica Yields Fluorosalinosporamide. J Nat Prod (2010) 1.39
Chasing the treasures of the sea - bacterial marine natural products. Curr Opin Microbiol (2009) 1.32
The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry (1995) 1.29
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol (2009) 1.28
Multigram synthesis of the C29-C51 subunit and completion of the total synthesis of altohyrtin C (spongistatin 2). J Am Chem Soc (2003) 1.27
Deep-sea hydrothermal vents: potential hot spots for natural products discovery? J Nat Prod (2010) 1.25
Libertellenones A-D: induction of cytotoxic diterpenoid biosynthesis by marine microbial competition. Bioorg Med Chem (2005) 1.25
Gram-scale synthesis of (+)-spongistatin 1: development of an improved, scalable synthesis of the F-ring subunit, fragment union, and final elaboration. Org Lett (2008) 1.23
Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol (2004) 1.22
GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem (1994) 1.22
Mixed fermentation for natural product drug discovery. Appl Microbiol Biotechnol (2009) 1.21
A functional genomics approach to the mode of action of apratoxin A. Nat Chem Biol (2006) 1.20
Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett (2000) 1.20
Loihichelins A-F, a suite of amphiphilic siderophores produced by the marine bacterium Halomonas LOB-5. J Nat Prod (2009) 1.20
A sea of biosynthesis: marine natural products meet the molecular age. Nat Prod Rep (2010) 1.19
Lymphostin (LK6-A), a novel immunosuppressant from Streptomyces sp. KY11783: structural elucidation. J Antibiot (Tokyo) (1997) 1.18
Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem (2008) 1.17
A tetrachloro polyketide hexahydro-1H-isoindolone, muironolide A, from the marine sponge Phorbas sp. natural products at the nanomole scale. J Am Chem Soc (2009) 1.14
Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14
Phorbasides A-E, cytotoxic chlorocyclopropane macrolide glycosides from the marine sponge Phorbas sp. CD determination of C-methyl sugar configurations. J Org Chem (2008) 1.14
Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds. Eur J Cancer (2008) 1.14
The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J Nat Prod (1993) 1.13
Microscale methodology for structure elucidation of natural products. Curr Opin Biotechnol (2010) 1.11
Recent advances and method development for drug target identification. Trends Pharmacol Sci (2009) 1.09
Developing tools for engineering hybrid polyketide synthetic pathways. Curr Opin Biotechnol (2006) 1.09
Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J Cell Biol (2009) 1.09
Bryostatins: biological context and biotechnological prospects. Curr Opin Biotechnol (2010) 1.09
Complex synthesis yields breast-cancer therapy. Nature (2010) 1.08
Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today (2006) 1.05
Marine natural products as sources of novel scaffolds: achievement and concern. Drug Discov Today (2010) 1.04
Palmerolide A, a cytotoxic macrolide from the antarctic tunicate Synoicum adareanum. J Am Chem Soc (2006) 1.03
Indole alkaloids from Cephalanceropsis gracilis. J Nat Prod (2006) 1.03
Total synthesis of apratoxin A. J Am Chem Soc (2003) 1.03
Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Curr Drug Discov Technol (2004) 1.02
Marine antifungal theonellamides target 3beta-hydroxysterol to activate Rho1 signaling. Nat Chem Biol (2010) 1.00
Finding the target after screening the phenotype. Drug Discov Today (2005) 1.00
Structure elucidation at the nanomole scale. 2. Hemi-phorboxazole A from Phorbas sp. Org Lett (2009) 0.97
The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: fragment couplings, completion of the synthesis, analogue generation and biological evaluation. Org Biomol Chem (2005) 0.96
Towards high-throughput characterization of small molecule mechanisms of action. Mol Biosyst (2006) 0.94
Achieving natural product synthesis and diversity via catalytic networking ex vivo. Chem Biol (1996) 0.94
Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs (1986) 0.93
Synthetic studies of cephalandole alkaloids and the revised structure of cephalandole A. J Nat Prod (2008) 0.93
Structure elucidation at the nanomole scale. 3. Phorbasides G-I from Phorbas sp. J Nat Prod (2010) 0.89
Unusual antimicrotubule activity of the antifungal agent spongistatin 1. Antimicrob Agents Chemother (1999) 0.88
Combinatorial libraries. Finding the needle in the haystack. Curr Biol (1994) 0.88
Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia (2008) 0.88
Frontiers and opportunities in chemoenzymatic synthesis. J Org Chem (2010) 0.86
Design, synthesis, and biological evaluation of EF- and ABEF- analogues of (+)-spongistatin 1. Org Lett (2010) 0.85
Characterization of picomole amounts of oligosaccharides from glycoproteins by 1H NMR spectroscopy. Angew Chem Int Ed Engl (2010) 0.77
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc (2008) 2.34
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc (2008) 1.76
A small-molecule inducer of the antioxidant response element. Chem Biol (2010) 1.65
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol (2010) 1.47
A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A (2007) 1.44
Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J Nat Prod (2007) 1.42
Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides. J Nat Prod (2007) 1.32
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol (2009) 1.28
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. J Nat Prod (2008) 1.28
Isolation and biological evaluation of 8-epi-malyngamide C from the Floridian marine cyanobacterium Lyngbya majuscula. J Nat Prod (2010) 1.27
Phylogenetic and chemical diversity of three chemotypes of bloom-forming lyngbya species (Cyanobacteria: Oscillatoriales) from reefs of southeastern Florida. Appl Environ Microbiol (2009) 1.17
Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole. Chembiochem (2009) 1.14
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther (2010) 1.13
Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. J Nat Prod (2010) 1.13
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem (2009) 1.09
Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett (2008) 1.07
Total structure determination of grassypeptolide, a new marine cyanobacterial cytotoxin. Org Lett (2008) 1.06
Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod (2010) 1.06
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity. ACS Med Chem Lett (2011) 1.02
Lyngbyastatins 8-10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena. Mar Drugs (2009) 1.01
Lyngbyoic acid, a "tagged" fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa. Mol Biosyst (2011) 0.97
Total synthesis and biological evaluation of grassypeptolide A. Chemistry (2013) 0.95
Kempopeptins A and B, serine protease inhibitors with different selectivity profiles from a marine cyanobacterium, Lyngbya sp. J Nat Prod (2008) 0.94
Grassypeptolides A-C, cytotoxic bis-thiazoline containing marine cyclodepsipeptides. J Org Chem (2010) 0.93
Largamides A-C, tiglic acid-containing cyclodepsipeptides with elastase-inhibitory activity from the marine cyanobacterium Lyngbya confervoides. Planta Med (2009) 0.93
The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog. Int J Cancer (2003) 0.93
Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya majuscula from Guam. J Nat Prod (2010) 0.92
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases. J Med Chem (2012) 0.92
Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria Phormidium spp. from Florida. J Nat Prod (2010) 0.92
Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2-ARE pathway. Free Radic Biol Med (2013) 0.91
Biological targets and mechanisms of action of natural products from marine cyanobacteria. Nat Prod Rep (2015) 0.90
Protection of human cultured cells against oxidative stress by Rhodiola rosea without activation of antioxidant defenses. Free Radic Biol Med (2009) 0.90
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells. J Med Chem (2013) 0.89
Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbya polychroa. J Nat Prod (2008) 0.88
Tiglicamides A-C, cyclodepsipeptides from the marine cyanobacterium Lyngbya confervoides. Phytochemistry (2009) 0.88
Caldora penicillata gen. nov., comb. nov. (cyanobacteria), a pantropical marine species with biomedical relevance. J Phycol (2015) 0.88
Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets (2012) 0.87
Combination therapy for renal cell cancer: what are possible options? Oncology (2011) 0.86
Malyngamide 3 and cocosamides A and B from the marine cyanobacterium Lyngbya majuscula from Cocos Lagoon, Guam. J Nat Prod (2011) 0.85
Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. hydnoides from Guam. J Nat Prod (2011) 0.85
Pitipeptolides C-F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula from Guam. Phytochemistry (2011) 0.84
Total synthesis of grassystatin A, a probe for cathepsin E function. Bioorg Med Chem (2012) 0.84
Continuing studies on the cyanobacterium Lyngbya sp.: isolation and structure determination of 15-norlyngbyapeptin A and lyngbyabellin D. J Nat Prod (2003) 0.83
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma? Oncol Rev (2011) 0.83
Amantelides A and B, Polyhydroxylated Macrolides with Differential Broad-Spectrum Cytotoxicity from a Guamanian Marine Cyanobacterium. J Nat Prod (2015) 0.82
In Vitro and In Vivo Osteogenic Activity of Largazole. ACS Med Chem Lett (2011) 0.82
Activation of the antioxidant response element by specific oxidized metabolites of linoleic acid. Prostaglandins Leukot Essent Fatty Acids (2009) 0.81
Weapons in disguise--activating mechanisms and protecting group chemistry in nature. Chemistry (2010) 0.80
Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity. J Med Chem (2014) 0.80
Intramolecular modulation of serine protease inhibitor activity in a marine cyanobacterium with antifeedant properties. Mar Drugs (2010) 0.80
Bioassay-guided isolation and identification of desacetylmicrocolin B from Lyngbya cf. polychroa. Planta Med (2009) 0.79
Marine cyanobacterial fatty acid amides acting on cannabinoid receptors. Chembiochem (2012) 0.79
In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway. ACS Chem Biol (2013) 0.78
Cultivated sea lettuce is a multiorgan protector from oxidative and inflammatory stress by enhancing the endogenous antioxidant defense system. Cancer Prev Res (Phila) (2013) 0.78
Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation. Chembiochem (2014) 0.78
Combination therapy targeting cancer metabolism. Med Hypotheses (2010) 0.77
Biological effects of Byrsocarpus coccineus in vitro. Pharm Biol (2010) 0.77
Modular strategies for structure and function employed by marine cyanobacteria: characterization and synthesis of pitinoic acids. Org Lett (2013) 0.77
Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata. J Nat Prod (2016) 0.75
Porpoisamides A and B, two novel epimeric cyclic depsipeptides from a Florida Keys collection of Lyngbya sp. Bioorg Med Chem (2011) 0.75
Construction and characterization of melanocortin-2 and -4 receptor chimeras. Adv Exp Med Biol (2009) 0.75
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer. J Nat Prod (2017) 0.75
Discovery, Synthesis, and Biological Evaluation of Anaenamides C and D from a New Marine Cyanobacterium, sp. J Nat Prod (2022) 0.75
Apratyramide, a Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing. ACS Chem Biol (2017) 0.75
Correction to Caylobolide B, a Macrolactone from Symplostatin 1-Producing Marine Cyanobacteria Phormidium spp. from Florida. J Nat Prod (2016) 0.75